China
Africa
Explore chapters and articles related to this topic
Menstrual-Cycle-Related Disorders
Published in Jane M. Ussher, Joan C. Chrisler, Janette Perz, Routledge International Handbook of Women’s Sexual and Reproductive Health, 2019
Nancy Fugate Woods, Nancy J. Kenney
Other factors may also underlie the experience of menstrual migraine. Trigeminal response to stimulation occurs at a shorter latency in women with MM during the perimenstrual period than during the follicular phase, a difference not observed with women without MM (Varlibas & Erdemoglu, 2009). Women’s pain perception increases during the late luteal phase, regardless of whether they experience migraine (de Tommaso, 2011). This may be why migraines that occur in the perimenstruum are rated as more painful and debilitating than migraines at other times of the menstrual cycle (de Tommaso et al., 2009). Elevated prostaglandin (Silberstein & Merriam, 1993) and/or low serotonin (Chauvel, Multon, & Schoenen, 2018) levels may also play a role in the experience of migraine pain.
A Study of Headache Intensity and Disability with the Menstrual Cycle
Published in Diana L. Taylor, Nancy F. Woods, Menstruation, Health, and Illness, 2019
Patricia Solbach, Lolafaye Coyne, Joseph Sargent
One type is the menstrual migraine headache—a one-sided, throbbing head pain usually associated with gastrointestinal upset, photophobia, and irritability (Solbach, 1985). The other type of headache is known as tension or muscle contraction headache, described as an ache or a sensation of tightness or pressure, usually in the frontal and occipital area and varying widely in frequency, duration, and intensity (Martin, 1983).
Migraine: diagnosis and treatment
Published in Stephen D. Silberstein, Richard B. Upton, Peter J. Goadsby, Headache in Clinical Practice, 2018
Stephen D. Silberstein, Richard B. Upton, Peter J. Goadsby
The prevalence of menstrual migraine depends upon the definition used and the population studies; in clinical-based series, the frequency of menstrual migraine has been reported to be as high as 60–70%. Based on retrospective analysis, prevalence ranges from 26% to 60% in headache clinic patients. The prevalence is lower in non-headache clinic patients. The relative frequency of menstrual migraine depends on the means of ascertainment.130 Women with migraine are more likely to have migraine headaches at the time of menses (Figure 6.21). Women with PMS have more headaches prior to the onset of menses, but most women have more headaches just before or with menstruation. Some women have migraine (usually without aura) only with menses. Menstrual migraine can be defined by looking at attacks triggered by menstruation on a regular basis (Table 6.25). Attacks that occur only with menstruation, even if infrequent, have been called ‘true menstrual migraine’. Attacks that occur both at menstruation and at other times of the month are termed ‘menstrually triggered migraine’. A frequency indicator (e.g. frequent >70%, common 35–70%, and infrequent <35%) would look at the tightness of this association. The quality of these attacks, their response to treatment, and the hormonal changes in such patients could then be analysed based on this association. Migraine attacks occurring 2–7 days before the onset of menses would be called ‘premenstrual’; those occurring from −1 to +4 days, ‘menstrual’. These cut-offs are arbitrary.129 In our view, the hormonal events surrounding menstruation trigger migraines in biologically vulnerable individuals; menstrual migraine is not a different type of migraine.
Device profile of Nerivio for the acute and preventive treatment of episodic or chronic migraine in patients 12 years and older
Published in Expert Review of Medical Devices, 2023
Mahsa Babaei, Alan M. Rapoport
Nerivio and its behavioral treatment application, provide an effective, well tolerated, safe, user-friendly, non-pharmacological and non-addictive acute and preventive treatment for episodic and chronic migraine in individuals aged 12 years and older. One study also demonstrated effectiveness in women with menstrual migraine. The device has been cleared by both FDA and CE and recommended by AHS as a tier 2 therapy for migraine patients who do not respond to initial therapy with a triptan, or when the initial choice of acute treatment has been intolerable or contraindicated. Additionally, those who seek a medication-free lifestyle may well benefit from this treatment. Nerivio has shown excellent efficacy, comparable with other migraine treatments, and causes few adverse effects, which adds to its popularity. The device, either alone or in combination with other treatments, has helped many patients to obtain maximized therapeutic outcome with significant return to normal functioning by 2 hours.
A randomized, double-blinded, placebo-controlled, parallel trial of vitamin D3 supplementation in adult patients with migraine
Published in Current Medical Research and Opinion, 2019
P. Gazerani, R. Fuglsang, J. G. Pedersen, J. Sørensen, J. L. Kjeldsen, H. Yassin, B. S. Nedergaard
Previously, two case report studies had shown that vitamin D was effective in reducing the frequency of migraine in four women28,29. One of these studies included two pre-menopausal women suffering from menstrual migraine and pre-menstrual syndrome, and the other included two post-menopausal women suffering from migraine. All four subjects were treated with a combination of vitamin D2 or D3 and calcium in varying doses. During these studies, all four subjects reported a decrease in frequency and duration of migraine attacks. The two pre-menopausal women also reported a relief of pre-menstrual syndrome, including related pain symptoms. Our findings also demonstrated a decrease in the frequency of migraine. A recent study has also demonstrated that simvastatin and vitamin D were effective in preventing headache in adults with episodic migraine30.
Menstrual migraine: a review of current and developing pharmacotherapies for women
Published in Expert Opinion on Pharmacotherapy, 2018
G. Allais, Giulia Chiarle, Silvia Sinigaglia, Chiara Benedetto
Migraine is one of the most common neurologic disorders in the general population. It is estimated to affect 18% of women and 6% of men, with increasing prevalence among women of reproductive age (24% in those aged between 30 and 39 years) [1]. Women have a 3.25 greater risk of suffering migraine attacks as compared to men [2]. Two types of migraine are clinically distinguished: migraine with aura (MA) and migraine without aura (MO) [3]. MO in over 50% of women is strongly correlated with the menstrual cycle and its hormonal fluctuations [4–6]: this clinical picture is generally described as menstrual migraine (MM). Although MM is highly prevalent among women migraineurs, the latest edition of the International Classification of Headache Disorders (ICHD III beta) of the International Headache Society (IHS) [3] distinguishes two types of MM, which are mentioned only in the Appendix, identified according to a set of diagnostic criteria alternative to those listed in the main body of the classification: Pure menstrual migraine (PMM) (A 1.1.1), affecting about 10% of female migraineurs, if attacks are limited solely during the perimenstrual window (PMW) that starts 2 days before the onset of menses and continues through the first 3 days of menstruation.Menstrually-related migraine (MRM) (A 1.1.2) that occurs during the PMW and any time during the menstrual cycle.